Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".
The study was led by Dr. Randy Loftus, MD, an Associate Professor of Anesthesiology and Critical Care Medicine at University of Iowa Hospital and Clinics, and Dr. Franklin Dexter, MD, PhD, University of Iowa Professor in the Department of Anesthesia.
The goal of the preclinical work was to investigate the following: to see if low-intensity pulsed ultrasound could enhance the therapeutic efficacy of anti-PD-1 in C57BL/6 mice – bearing intracranial GL261 gliomas; epidermal growth factor receptor variant III (EGFRvIII) specific chimeric antigen receptor (CAR) T cells within NSG mice with established EGFRvIII-U87 gliomas (epidermal growth factor receptor variant III); and a genetically-engineered antigen-presenting cells (APC)-based therapy, producing the T-cell attracting chemokine CXCL10 in the GL261-bearing mice
“The first cases demonstrate fast application and easy activation of the NPsealTM” stated Machiel van der Leest, CEO of Guard Medical. “This ease of use combined with its cost effectiveness makes prophylactic use of NPWT for closed surgical wounds possible.”
“This is another enormous milestone for our company and a testament to the ease-of use and durable clinical efficacy of TWO2 therapy, as well as to the tenacity of our entire dedicated care team. AOTI
Both patients were given access to Hemopurifier® treatment through Emergency Use. The manuscript is titled "Removal of COVID-19 Spike Protein, Whole Virus, Exosomes and Exosomal microRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients with COVID-19 Infection" and was published in Research Square.
IRRAflow Intraventricular Hemorrhage (IVH) Case Report Published in Cureus Journal of Medical Science. Publication also documents the ability to deliver targeted thrombolytic medication via IRRAflow's recurring irrigation for the first time in the peer-reviewed scientific literature
Conducted at the Richard L. Roudebush VA Medical Center in Indianapolis, the study evaluated the safety, tolerability and performance of the FAST Technology in chronic dialysis patients with extremely reduced or no kidney function.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
